Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $18.0K | $24.0K | $51.8M | $60.9M | $378M | $63.5M | $140M |
| Revenue growth | — | 33.3% | 215916.7% | 17.5% | 520.0% | -83.2% | 120.0% |
| Operating income | -$75.2M | -$133M | -$392M | -$338M | -$176M | -$416M | -$384M |
| Operating margin | -417522.2% | -553166.7% | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% |
| Net income | -$78.3M | -$195M | -$371M | -$289M | -$133M | -$377M | -$80.0M |
| Net margin | -435144.4% | -810800.0% | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% |
| EPS (diluted) | -$14.05 | -$4.19 | -$5.77 | -$4.13 | -$1.72 | -$4.58 | -$0.81 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$72.0M | -$95.7M | -$66.3M | $22.5M | -$149M | -$347M | -$345M |
| Capital expenditures | $12.5M | $16.4M | $46.8M | $49.0M | $33.7M | $8.95M | $14.9M |
| Free cash flow | -$84.5M | -$112M | -$113M | -$26.4M | -$183M | -$356M | -$360M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $37.2M | $162M | $560M | $233M | $436M | $282M | $295M |
| Total assets | $156M | $452M | $1.47B | $1.34B | $1.46B | $1.10B | $1.48B |
| Total liabilities | $55.2M | $206M | $648M | $608M | $478M | $370M | $243M |
| Shareholders' equity | -$201M | $246M | $827M | $733M | $981M | $734M | $1.24B |
| Retained earnings | -$203M | -$398M | -$768M | -$1.06B | -$1.19B | -$1.57B | -$1.64B |
| Shares (wtd avg diluted) | 6.48M | 46.7M | 64.2M | 70.0M | 77.2M | 82.3M | 98.9M |
Every figure is extracted from Beam Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.